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Background: Diverse studies have evidenced that chemokines can play a critical role in pathogenesis of oral squa-
mous cell carcinoma (SCC). The main chemokines involved in oral carcinogenesis, tumor invasion and metastasis 
are CCR4, CCR5, CCR7 and CXCR4, and our aim was to evaluate the prognostic value of the immunoexpression 
of these chemokines in SCC of tongue and floor of the mouth.
Material and Methods: A retrospective descriptive study of the immunohistochemical expression of CCR4, CCR5, 
CCR7 and CXCR4 in paraffin-embedded samples of 124 patients with SCC of the tongue and floor of the mouth 
was performed, considering 98 cases from Brazil and 26 cases from Chile. Associations between variables were 
analyzed using chi-square test. Survival curves were performed using the Kaplan-Meier method and compared 
with long-rank test. For multivariate survival analysis, the Cox hazard model was established. The level of signifi-
cance established was p≤0.05.
Results: The statistical analysis showed that samples with well or moderate WHO model differentiation (p=0.001) 
and a high expression of  CCR5 (p=0.05) were significantly associated with a higher disease specific survival, 
which were also observed in Cox ś multivariate analysis (p=0.01). A higher expression of CCR7 (p=0.01) inter-
fered significantly in disease-free survival in univariate analysis and in Cox ś multivariate analysis (p=0.05).
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Introduction
Squamous cell carcinoma (SCC) is a malignant neo-
plasm, accounting for more than 90% of malignancies 
in the oral cavity (1). It is more frequent in men after the 
fifth decade of life, but interestingly, recent epidemio-
logical studies have suggested that 4 to 6% of oral can-
cer cases in the world have occurred in young adults, 
aged 18-45 years (2).  The etiology is multifactorial, 
with extrinsic and intrinsic factors contributing to the 
development of this disorder. The most correlated env-
vironmental factor is tobacco smoking and exposure of 
the mucosa to alcohol (3). The human papillomavirus 
(HPV), is especially associated with oropharyngeal car-
cinoma and its association with oral cavity cancer in not 
conclusive (4).
The treatment of these patients is based on surgery, ra-
diotherapy and/or chemotherapy, that can include neck 
dissection when lymphadenopathy is evidenced, but oc-
cult cervical metastasis can occur (5). Despite the ad-
vances in research and treatment options, the prognosis 
of patients with oral SCC has remained practically static 
in the last decades, remaining between 50 and 60% for 
a period of 5 years (6). This low survival rate is mainly 
due to late diagnosis, local invasion and high propensity 
for regional and distant dissemination (7).
For many years, research in carcinogenesis and cancer 
progression focused on tumor cells, especially genetic 
and epigenetic alterations. However, it has been re-
vealed that cancer is a more complex disease, involving 
strong interactions between cells of the tumoral micro-
environment (TM) and others components of extracel-
lular matrix (ECM), including carcinoma-associated 
fibroblasts (CAFs), immune and inflammatory, and sup-
porting blood and lymphatic endothelial cells (8).
Chemokines are small chemotactic cytokines that play 
a key role in tumor progression, migration, leukocyte 
activation, angiongenesis and metastasis. Some studies 
report that cytokines may have different effects on the 
tumor, being able to keep the phenotype invasive (9). 
These molecules act by selective membrane, that are 
linked to seven G-protein-coupled receptors (GPCRs) 
that present two main families, CCR and CXCR (10). 
Chemokines are classified in four groups, according to 
conservation and spacing of cysteines in CXC, CC, C 
and CX3C (11). Have been reported that CXCR4 medi-
ate growing signals and promote metastasis (10), CCR5 
acts in recruitment of effector cells and antigen-present-
ing cells (macrophages) (12), CCR4 and CCR7 has been 
Conclusions: These results support additional evidence, showing that chemokine receptors CCR5 and CCR7 are 
helpful as biomarkers of poor prognosis in patients with SCC of the tongue and floor of the mouth.
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associated to the ability of neoplastic cells to promote 
lymph node metastasis. CCR7 can also promote the pro-
liferation of neoplastic cells, adhesion, migration, inva-
sion and angiogenesis in oral tumorigenesis (9). 
Chemokine receptors play a key role in the develop-
ment, progression and metastasis of cancer, and were 
reported in various types of cancer, as kidney (13), ova-
ry (14), and head and neck SCC (9,15). Our group previ-
ously reported the immunohistochemical expression of 
CCR1, CCR3, CCR4, CCR5, CCR7 and CXCR4 in SCC 
of the head and neck (oral cavity, oropharynx and lar-
ynx), suggesting an important role of CCR5 and CCR7 
in cancer progression (15). Diverse studies reported that 
chemokines can also play a critical role in pathogenesis 
and progression of oral SCC (9,12,15).  Based on these 
arguments, the aim of the current study was to evalu-
ate the prognostic value of the immunohistochemical 
expression of CCR4, CCR5, CCR7 and CXCR4 related 
to clinicopathological parameters in samples of SCC of 
tongue and floor of the mouth.
Material and Methods
-Patients and sample collection
Herein we are reporting a retrospective descriptive 
study of the immunohistochemical expression of CCR4, 
CCR5, CCR7 and CXCR4 in paraffin-embedded tissues 
of 98 cases from Hospital do Bom Pastor (Varginha-
MG, Brazil) and 26 cases from Hospital Carlos van 
Buren (Valparaíso, Chile), between 1998 and 2014. 
Clinicopathological data was collected from patients’ 
files. All histopathological slides were revised and the 
clinical stage was re-diagnosed according to the Eighth 
edition of the American Joint Committee on Cancer 
(AJCC) Staging Manual, Head and Neck Section (16). 
Inclusion criteria chosen for this study were: 1- patients 
with a diagnosis of OSCC of tongue and floor of the 
mouth, and treated at this hospital, 2- surgical treatment 
performed according to standard procedure and consist-
ing of resection of the primary tumor, 3- clinicppatho-
logical data and samples of paraffin-embedded tumor 
for evaluation. The blocks were kindly provided by IPD 
Laboratory (Institute of Diagnostic and Prevention) of 
Varginha, Brazil, responsible for anatomopathological 
analysis of all samples of the Hospital Bom Pastor, and 
the Anatomic Pathology Service of the Hospital Carlos 
van Buren of Valparaíso, Chile.
The parameters obtained in the medical charts of each 
patient were: age, gender, smoking and drinking habit, 
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tumor localization (tongue or floor of month), clinical 
stage, treatment (surgery, surgery associated with ra-
diotherapy or surgery associated with radiotherapy and 
chemotherapy), margins status, lymph node involve-
ment, perineural invasion, lymphocytic response and 
recurrence/ metastasis (local, lymph node, distance or 
not). The exclusion criteria considered poor information 
or insufficient tissue for immunohistochemical reac-
tions.
The study was approved by the Ethics Committee in 
Research of the, Federal University of Alfenas (protocol 
number: 1.775.304) and University of Valparaíso, Chile 
(protocol number: CB 051-14).
-Immunohistochemical staining and analysis
Histological sections at 3μm were diaphanized in three 
sequences Histological Clearing Agent, Histo-Clear 
(National Diagnostic), hydrated in three decreasing con-
centrations of alcohol and distilled water. The antigen 
retrieval procedure, was performed using EnVision™ 
Flex Target Retrieval Solution (Dako) at 95 °C for 20 
min, followed by endogenous enzyme block (EnVision 
FLEX peroxidase-blocking reagent) for 5 min, and the 
sections were incubated with primary antibodies CCR4 
(rabbit, polyclonal antibody PA532698, dilution 1:200, 
Invitrogen Inc., USA), CCR5 (rabbit, polyclonal anti-
body PA529011, dilution 1:500, Invitrogen Inc., USA), 
CCR7 (rabbit, polyclonal antibody PA533401, dilution 
1:150, Invitrogen Inc., USA) and CXCR4 (rabbit, poly-
clonal antibody PA3305, dilution 1:1000, Invitrogen 
Inc., USA), overnight at 4ºC. The next day, EnVisionTM 
Flex Mouse Linker was added for 15 min (excluding 
cases with primary antibody CXCR4), and EnVision 
FLEX / HRP for 30 min, the revelation was incubation 
with diaminobenzidene (DAB) chromogen, the slides 
were counterstained with hematoxylin.
The immunohistochemical analysis was applied with a 
semiquantitative scoring system according to a previ-
ously published method. This visual method was per-
formed by two observers at the same time and defined 
two evaluation criteria (Fig. 1):
• Percentage of positive cells with, 0 (negative), 1 (1%–
25%), 2 (26%–50%), 3 (51%–75%) and 4 (76%–100%) 
Fig. 1. Low/negative, moderate and high staining intensity for CCR4 (A,B,C), CCR5 (D,E,F), CCR7 (G,H,I) and 
CXCR4 (J,K,L) (20x objective).





Disease-specific survival Disease-free survival
% in 5 
years
HR (95% CI) / p value % in 5 
years
HR (95% CI) / p value
Age      
≤62 years 63 (50.8) 51.4 1 66.5 1
>62 years 61 (49.2) 75.1 0.88 (0.43-1.82) / 0.73 77.0 0.99 (0.43-2.27) / 0.99
Gender      
Male 82 (66.1) 64.4 1 75.6 1
Female 42 (33.9) 67.0 1.11 (0.52-2.37) / 0.77 67.6 0.81 (0.35-1.91) / 0.64
Smoking habit      
No 17 (17.0) 52.3 1 57.3 1
Yes 83 (83.0) 68.4 0.74 (0.27-2.00) / 0.50 77.5 0.67 (0.22-2.09) / 0.43
Drinking habit      
No 32 (34.4) 64.9 1 58.8 1
Yes 61 (65.6) 63.2 1.36 (0.60-3.03) / 0.45 79.9 0.78 (0.31-1.92) / 0.57
Tumor site      
Tongue 91 (73.4) 64.9 1 75.7 1
Floor of the mouth 33 (26.6) 72.2 0.70 (0.31-1.58) / 0.42 70.6 1.03 (0.40- 2.62) / 0.94
Clinical stage      
   I / II 44 (35.5) 78.1 1 75.4 1
   III / IV 76 (61.3) 59.4 1.85 (0.89-3.92) / 0.03 71.3 1.002 (0.44-2.23) / 0.53
Treatment      
Surgery 24 (20.2) 82.8 1 71.2 1
Surgery / RTX 43 (36.2) 67.0 1.14 (0.42-3.13) 85.1 0.75 (0.25-2.29)
Surgery / RTX / CTX 52 (43.6) 58.3 1.32 (0.50-3.46) / 0.84 66.8 1.67 (0.56-5.00) / 0.19
Margins status      
Negative 61 (59.3) 78.6 1 76.4 1
  Positive 42 (40.7) 50.1 2.13 (0.87-5.20) / 0.05 57.1 1.58 (0.61-4.05) / 0.27
Lymph node involvement      
No 65 (53.7) 79.0 1 78.0 1
Yes 56 (46.3) 51.6 1.94 (0.93-4.06) / 0.07 67.7 1.54 (0.68-3.51) / 0.26
Table 1. Clinical and pathological features and univariate analysis for disease-specific survival and disease-free survival of patients with squa-
mous cell carcinoma of tongue and floor of the mouth.
• Stain intensity with, 0 (negative), 1 (weak), 2 (moder-
ate) and 3 (intensive staining). 
The final score was obtained by multiplying the per-
centage of positive cells with the stain intensity score, 
and was classified as low expression (score 0-3) and 
high expression (score 4-12) (15).
-Statistical analysis
The level of significance established was p≤0.05. 
Curves for analysis of disease-specific survival and dis-
ease-free survival were using the Kaplan-Meier meth-
od and compared with long-rank test, for multivariate 
survival analysis, the Cox proportional hazard model 
with a stepwise method was established. Associations 
between clinicopathological parameters and immuno-
histochemical expression of CCR4, CCR5, CCR7 and 
CXCR4 using the chi-square test were also analyzed.
Results
The clinicopathological features of the studied popula-
tion is summarized in Table 1, 1 continue. Eighty-two 
patients (66.1%) were men, with a median-age of 62 
years-old. Eighty-three (66.9%) patients were smokers 
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Lymphocytic response      
  Weak / Moderate 98 (79.0) 67.6 1 81.1 1
Intense 26 (21.0) 55.3 1.65 (0.67-4.97) / 0.23 44.0 2.05 (0.80-8.43) / 0.11
WHO grading system      
Well / Moderately 116 (93.5) 68.4 1 74.0 1
Poor 8 (6.5) 0.0 4.76 (0.60-37-26) / 0.001 50.0 2.58 (0.11-59.59) / 0.32
CCR4      
Low expression 28 (22.9) 73.3 1 74.2 1
High expression 94 (77.1) 65.1 1.10 (0.43-2.82) / 0.82 76.3 1.39 (0.47-4.51) / 0.50
CCR5      
Low expression 74 (60.6) 71 1 77.4 1
High expression 48 (39.4) 53.1 1.93 (0.97-4.74) / 0.05 67.3 1.59 (0.65-4.73) / 0.25
CCR7      
Low expression 36 (29.5) 72 1 100.0 1
High expression 86 (70.5) 60.4 1.28 (0.59-2.82) / 0.51 63.1 3.83 (1.21-6.93) / 0.01
CXCR4      
Low expression 9 (7.4) 40.6 1 80 1
High expression 113 (92.6) 67.3 1.98 (0.60-10.22) / 0.18 74 1.38 (0.27-7.96) / 0.65
Table 1 continue. Clinical and pathological features and univariate analysis for disease-specific survival and disease-free survival of patients 
with squamous cell carcinoma of tongue and floor of the mouth.
RTX = radiotherapy; CTX = chemotherapy; HR = hazard ratio; CI = confidence interval.
and 61 (49.2%) reported alcohol consumption. Regard-
ing T stage, 68 patients (54.8%) were classified as T1/
T2 and 52 patients (41.9%) as T3/T4. In the N stage, 
the highest prevalence was N0 with 68 patients (54.8%), 
followed by 24 patients (19.3%) with N1, and 22 patients 
(17.7%) with N2. Forty-four patients (35.5%) were clas-
sified as clinical stage I or II (early stage) and 76 (61.3%) 
were classified at advanced clinical stage (stages III or 
IV). Four patients did not present the TNM stage in their 
medical records. Surgery as exclusive therapy was per-
formed in 24 patients (19.3%), whereas 43 (34.7%) were 
treated by combination of surgery and radiotherapy and 
52 (41.9%) had the combination of surgery, radiotherapy 
and chemotherapy (Table 1, 1 continue). 
The analysis of immunohistochemical markers showed 
that 39.4% (n=48) of cases had a high expression for 
CCR5, 69.3% (n=86) for CCR7, 75.8% (n=94) for CCR4, 
and 91.1% (n=113) for CXCR4. Most surgical pieces pre-
sented negative margins (59.3%, n=61) and perineural 
invasion (53.2%, n=66). From 124 patients evaluated, 
91 (73.4%) received cervical resection. The results re-
vealed that 93.5% of cases (n=116) were classified as 
well/moderate differentiated according to WHO clas-
sification system (Table 1, 1 continue). The overall sur-
vival ranged from 1 to 136 months, with a mean of 90 
months for disease-specific survival and 91 months for 
disease-free survival. Six patients were excluded from 
the evaluation of survival analysis because the lack of 
information in their medical records.
In the univariate analysis, was observed that clinical 
stage (p=0.03), positive surgical margins (p=0.05), 
poor differentiation (p=0.001) and CCR5 expression 
(p=0.05) revealed significance for specific survival of 
disease and a high expression of CCR7 (p=0.01) inter-
fered with disease-free survival (Table 1, 1 continue). 
However, in the Cox’s multivariate analysis, poor dif-
ferentiation (p=0.01) is significant for specific survival 
(Table 2) and high expression of CCR7 (p=0.05) for 
free-disease survival (Table 3).
Association between immunohistochemical expression 
of CCRs and clinicopathological features are showed in 
Table 4, 4 continue. A significant association between 
the immunoexpression of CCR4 and positive margins 
(p=0.01) was observed. For CCR5, was identified that 
clinical staging (p=0.05) and intense lymohocytic re-
sponse (p=0.01) were significant. CCR7 showed signifi-
cance with gender (p=0.02) and recurrence (p=0.05). 
CXCR4 was expressed in a high number of tumors, 
mainly in the center of islands, with a less intense ex-
pression in the borders of islands, for this reason it did 
not show any association with clinicopathological pa-
rameters.
Discussion
SCC is a malignant neoplasia of epithelial origin that 
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Parameters Disease-specific survival
HR (95% CI) p value
WHO grading system
Well / Moderately 1
0.01Poor 7.21 (1.51-34.33)
Table 2. Multivariate Cox analysis for disease-specific survival in patients with 
squamous cell carcinoma of tongue and floor of the mouth.
Note: (HR) hazard ratio and (CI) confidence interval.
Parameter Disease-free survival
HR (95% CI) p value
CCR7
Low expression 1
0.05High expression 3.41 (1.00-11.76)
Table 3. Multivariate Cox analysis for disease-free survival in patients with 
squamous cell carcinoma of tongue and floor of the mouth.
Note: (HR) hazard ratio and (CI) confidence interval.
represents more than 95% of malignant tumors of oral 
cavity, and accounts for almost 4% of malignancies of 
humans (17,18). It is frequently diagnosed in advanced 
stage, and in our sample 61.3% (n=76) of patients were 
diagnosed in advanced stage (III or IV), which is as-
sociated with an elevated propensity for local invasion, 
regional and distant dissemination. The identification of 
potential new prognostic markers could help to determi-
nate an accurate prognosis for oral SCC.
The traditional histopathologic WHO gradation system 
showed positive association in univariate analysis for 
disease specific survival (p=0.001). Despite these re-
sults, many studies report that the application of WHO 
classification to predict the prognosis in patients with 
SCC have been criticized because the absence of im-
portant features related to tumorigenesis, such as tumor 
thickness, vascular invasion, margins evaluation and re-
gional lymph nodes) (18), in addition to the subjectivity 
in the sample analysis and the weak correlation with the 
response to the therapy (16,19).
The current study revealed that the immunohistochemi-
cal expression of CCR5 showed significance for disease 
specific survival in univariate analysis (p=0.05), and 
when it was compared with clinicopathological pa-
rameters, was observed significance with clinical stage 
(p=0.05) and lymphocytic response (p=0.01). Some 
studies demonstrated that CCR5 is an unfavorable 
marker in patients with cancer of breast (20), colon (21), 
pancreas (22) and melanoma (23). CCR 5 has two li-
gands, CCL3 and CCL5, and recently was reported that 
the axis composed by CCR5 and associated chemokines 
has pro-tumorigenic effect, playing an important role in 
oral cancer progression (24).
Some studies reveal that T cells have a crucial role in the 
modulation of antitumoral immune response. De Olivei-
ra et al. demonstrated, that T cell migration to the tumor 
microenvironment is mediated by CCR5, promoting the 
SCC growing, through inhibition of antitumoral cells. 
Other study reveals that migration and death of oral tu-
mor cells mediated by T cells, have the participation of 
CCR5, suggesting a new approach through modulation 
of CCR5 signals in monocytes and macrophages (12). 
Previous research reported that monocytes of patients 
with oral SCC present significantly reduced levels of 
CCR5 and reduction of migration when are compared 
with healthy patients. Migration of leukocytes is fun-
damental for the antitumoral activity of monocytes and 
macrophages, and this reduction can facilitate the sup-
pression of the immunological system of patients with 
oral SCC (26). Gonzalez-Arriagada et al., reported in 
samples of head and neck SCC, that CCR5 is associated 
to advanced stage, lymph node metastasis and lower 
survival. The current data show that patients with SCC 
of tongue and floor of the mouth, with a higher expres-
sion of CCR5, are associated with advanced clinical 
stage and worse prognosis. Recently was reported that 
the CCR5 antagonists reduce tumor growth and pro-
gression of colon cancer cells (27). For these reasons, 
we suggest that CCR5 is a chemokine that can permit 
a therapeutical approach to the treatment of SCC of 
tongue and floor of the mouth.
Metastasis is a mechanism that depends of the migration 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































through the extracellular matrix, adhesion to the vascu-
lar endothelium, invasion of blood vessels, extravasa-
tion and growing in a secondary organ (28). CCR7 have 
two ligands, CCL19 and CCL21. CCL19 is expressed in 
lymphoid tissues (28) and it can promote cellular migra-
tion and adhesion, favoring the metastasis (Fig. 2). 
Additionally, we observed that the high expression of 
Fig. 2. CCRs has chemokines as ligands. Chemokines are re-
leased by lymphoid CAFs, promoting lymphangiogenesis and 
migration of CCR+ neoplastic cells to lymph nodes.
CCR7, presented significance for disease-free survival 
in univariate analysis (p=0.01) and Cox’s multivariate 
analysis (p=0.05). CCR7 also showed correlation with 
clinicopathological parameters, such as genre (p=0.02) 
and recurrence/metastasis (p=0.05). Retrospective 
studies about diverse neoplasias showed that tumor 
cells that express CCR7 are present in cancer of breast 
(29), colorectal (30) and pancreas (31).
It was reported in tongue SCC that the high immunohis-
tochemical expression of vascular endothelial growth 
factor C (VEGF-C), vascular endothelial growth fac-
tor receptor 3 (VEGFR-3), CCR7 and semaphorin 3E 
(SEMA3E) are predictors of metastasis. It was demon-
strated that these factors can be useful to evaluate me-
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tastasis in lymph nodes of SCC, with the aim to improve 
the oral SCC patients’ survival after treatment (32). Pre-
vious research reported that CCR7 regulate metastasis 
in head and neck SCC (28,33,34,35). The importance 
of the signaling way Janus activated kinase-3 (Jak3) in 
the metastasis of malignant head and neck tumors me-
diated by CCR7 and its ligands, can be a new target for 
treatment of these patients (36). Also, was reported that 
CCR7 can activate JAK2/STAT3 and to promote metas-
tasis. In this way, CCR7/JAK2/STAT3 regulate metas-
tasis by E-cadherin mediated epithelial-mesenchymal 
transition (EMT) (33). EMT represents a biologic pro-
cess that allows biochemical, molecular and morpho-
logical modifications in a polarized epithelial cell, that 
normally interacts with basal membrane. These modi-
fications result in the acquisition of a mesenchymal cell 
phenotype, with the capacity of migration, invasion and 
resistance to apoptosis (37). The role of CCR7 immu-
noexpression to predict cervical lymph node metastasis 
of oral SCC has been previously reported (38), so our 
results confirm the predictive utility of this marker in 
oral cancer.
Recently, CCR7 was associated with recurrence, gen-
der, smoking habit and bad prognosis in head and neck 
cancer (15). Our results demonstrated that patients with 
SCC of tongue and floor of the mouth and a high ex-
pression of CCR7 are associated with gender and recur-
rence/metastasis. In this way, CCR7 can allow that SCC 
cells of tongue and floor of the mouth become more in-
vasive and pro-metastatic, suggesting a therapeutic ap-
proach of these patients.
Conclusions
Finally, our results show that CCR7 and CCR5 can be 
helpful as prognostic markers and as a therapeutic ap-
proach of patients with SCC of tongue and floor of the 
mouth. The association of CCR5 and CCR7 chemokine/
chemokine receptor axis with poor prognosis in oral 
SCC needs future molecular research to study mecha-
nisms that lead to tumor growth and progression, con-
sidering that immunohistochemical studies can only 
confirm statistical relationship. 
We suggest the name oncochemotaxis for the mecha-
nism that lead the malignant cells to invasion and mi-
gration to the lymph node through the expression of 
chemokine receptors in its surface attracted by chemo-
kines.
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